Starpharma cancer drug shows good PK profile
20 October, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) said preliminary analysis of the pharmacokinetic profile of DEP-docetaxel shows superior duration of exposure compared to the reference drug.
Sirtex completes SIRFLOX trial
20 October, 2014 by Dylan Bushell-EmblingSirtex Medical (ASX:SRT) has completed its SIRFLOX trial of its SIR-Spheres in inoperable liver cancer and is making progress recruiting patients in three other trials.
Prima's M&A target lines up AU cancer patent
15 October, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has announced that Immutep, the cancer immunotherapy company it has proposed to acquire, will be receiving an Australian patent covering its technology.
Biotron to raise $4.1m for BIT225 IND
15 October, 2014 by Dylan Bushell-EmblingBiotron (ASX:BIT) has launched a $4.1m rights issue to fund trials and US IND preparation work for BIT225 in hepatitis C.
Bionomics' BNC105 improves survival in tumour model
14 October, 2014 by Dylan Bushell-EmblingA preclinical trial evaluating combining Bionomics' BNC105 with major cancer drugs Avastin, Votrient or Afinitor has delivered promising results.
Alchemia enters analysis stage for mCRC trial
13 October, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) expects to be ready to announce the results of its key phase III trial of HA-Irinotecan in metastatic colorectal cancer by the end of the month.
Biotron's BIT225 effectively cures HCV in pilot trial
10 October, 2014 by Dylan Bushell-EmblingAll five HCV genotype 3 patients completing treatment during a pilot trial of BIT225 with IFN/RBV had undetectable virus levels 12 weeks post-treatment.
Campaigning for medical research funding
08 October, 2014 by Brendan CrabbWith the potential to transform medical research, the Medical Research Future Fund needs the science community to get behind it.
A mathematical perspective for evolutionary biologists
07 October, 2014 by Susan WilliamsonA new mathematical method provides a more efficient way to mine and analyse genetic data.
Prima BioMed to buy Immutep for up to $32m
03 October, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has proposed to buy immuno-oncology company Immutep, in what chair Lucy Turnbull considers to be the most significant move in the company's history.
Genes indicate resistance to malaria
02 October, 2014A study on the human genetics of malaria has found that certain genes determine a person's level of resistance to this disease.
Patrys gets first Australian patent for PAT-LM1
30 September, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has been awarded its first Australian patent for PAT-LM1, an antibody that has shown strong anti-cancer potential during lab trials in blood cancers.
Bionomics, Viralytics, STA present cancer trial data at EMSO
30 September, 2014 by Dylan Bushell-EmblingBionomics, (ASX:BNO) Viralytics (ASX:VLA) and STA have presented strong data from cancer trials at ESMO 2014 in Spain.
Patrys CEO stepping down after four years
24 September, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) CEO and Managing Director Dr Marie Roskrow has tendered her resignation, effective at the end of the year.
Virax adds myeloma expert to scientific board
24 September, 2014Virax Holdings (ASX:VHL) has now added a multiple myeloma expert to its scientific advisory board, after picking a breast cancer expert in July.
